Infusion Drug Delivery News

  1. Terumo Pharmaceutical Solutions Expands CDMO Services Outside Japan For Global Market 10/31/2022

    Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.

  2. scPharmaceuticals Announces FDA Approval Of FUROSCIX® (Furosemide Injection) 10/11/2022

    scPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.

  3. Race Develops Improved IV Formulation Of Zantrene 9/28/2022

    ​Race Oncology Limited (“Race”) is pleased to announce that Race researchers, led by Dr Benjamin Buckley in collaboration with the University of Wollongong (ASX Announcement: 8 November 2021), have developed a new formulation of Zantrene that enables peripheral (arm or leg vein) intravenous (IV) delivery to patients

  4. West Makes Minority Investment In Dublin-Based Latch Medical, A Developer Of Vaccine And Biologics Delivery Platforms 8/15/2022

    West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.

  5. Societal CDMO Announces Key New Customer Project Within Automated Fill/Finish And Lyophilization Unit At San Diego Facility 6/8/2022

    Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced a key new customer project utilizing its automated fill/finish line and lyophilization unit at the company’s San Diego facility

  6. Sanofi Announces €300 Million Collaboration With Blackstone Life Sciences To Advance An Innovative Treatment For Multiple Myeloma 3/15/2022

    Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM).

  7. B. Braun Receives FDA Approval Of Daytona Beach Pharmaceutical Manufacturing Site 1/31/2022

    The site will produce 0.9% Sodium Chloride for Injection available in B. Braun's Excel® Plus IV Bags in 1,000 mL and 500 mL sizes.